Livagen (20mg)


Size: 20mg
Contents: Livagen (20mg)
Form: Lyophilized powder
Purity: >99%
SKU: P-Livagen

FREE Shipping on $200+ orders

FREE Bacteriostatic Water (30ml) on $200+ orders

Discount per Quantity

5 - 85%$65.55
9 +10%$62.10
SKU: P-Livagen Category:


Livagen Peptide

Livagen is a short peptide containing four amino acids: lysine, alanine, aspartic acid, and glutamic acid. Considered to be a bioregulator, this peptide may act on the DNA structure and impact functionality. The primary potential of Livagen is seen in how it acts on chromatin, DNA and genes.

Scientists have formalized that DNA is a double helix structure surrounded by proteins called "histones". These histones bind together, forming chromatin, and several chromatins then condense together, forming the chromosomes. These chromosomes appear to be crucial to forming genetic material specific to each being.(1)

Livagen has been considered by researchers for its potential to 'de-condense' these chromatin materials. As a result, some genes that had become non-functional in aged test subjects might become active, possibly improving cell activity and production.(2) Researchers posit that Livagen may potentially increase energy levels, skin elasticity, and possibly induce improvements in immune system functionality via this mechansim.


Livagen peptide, upon presentation, has been suggested by researchers to act on the lymphocytes, possibly reactivating the ribosomes by 'unpacking' the chromatin and modifying the gene expression. These lymphocytes are a type of white blood cell that is considered essential in attacking foreign impurities entering the system and enhancing immunity. In this manner, Livagen may exhibit potential to improve the immune system by coordinating cellular responses and controlling inflammatory responses.(3) T. Lezhava et al., who conducted a clinical research study on 75 to 88-year-old test subjects, stated that “These results indicate that peptide bioregulators Epitalon, Livagen, and Vilon cause activation (deheterochromatinization) of chromatin in lymphocytes of old individuals.”


Livagen Research and Clinical Studies

  • Cardiac disorders such as hypertrophic cardiomyopathy (HCM), atherosclerosis, and cardiac injury are considered to be characterized by dysregulation in chromatin structure. A bioregulatory peptide such as Livagen has been suggested by researchers to enact potential mitigation of these disfunctions. Studies(4)(5) have suggested that Livagen peptides may help reduce specific long-term impacts of such heart disorders. (5)
  • Another study(6) focused on peptide presentation in the presence of cobalt ions to evaluate their combined potential on chromatin structures. The study suggested that this combination possibly induces the de-condensation of chromatin. The results of this study are stated to be critical “because it provides new information about the protective effect of Livagen and Livagen + Cobalt ions on the lymphocytes of HCM patients and their relatives and may lead to the development of a therapeutic treatment.”(6)
  • Enkephalins are considered to be naturally occurring proteins that may bind with delta receptors and reduce pain. Bioregulatory peptides such as Livagen may possibly act on enzymes and prevent the degradation of these proteins, possibly increasing enkephalin levels.(7)
  • Livagen peptides may have potential in mitigating gastrointestinal disregulation. Livagen has been suggested by researchers to possibly increase the signaling stimuli by the vagal nerve in the gastrointestinal tract, leading to increased prostaglandins and nitric oxide synthesis. This enhanced production may, in turn, produce significant gastroprotective properties, preventing severe ailment.(8)
  • DNA alteration over time is considered to lead to increased condensation of chromatin and decreased cellular repair. The Livagen peptide has been suggested by researchers to inhibit and possibly reverse these alterations, improving cellular functions and 'reversing' aging.(9) Besides aging, specific chromosomal abnormalities may also be addressed through Livagen, based on the exact mechanism.

Livagen peptide is available for research and laboratory purposes only. Please review and adhere to our Terms and Conditions before ordering.


  1. National Human Genome Research Institute. Chromatin. May 10, 2022.
  2. Khavinson VKh, Lezhava TA, Monaselidze JG, Dzhokhadze TA, Dvalishvili NA, Bablishvili NK, Ryadnova IY. Effects of Livagen peptide on chromatin activation in lymphocytes from old people. Bull Exp Biol Med. 2002 Oct;134(4):389-92.
  3. Lezhava T, Monaselidze J, Kadotani T, Dvalishvili N, Buadze T. Anti-aging peptide bioregulators induce reactivation of chromatin. Georgian Med News. 2006 Apr;(133):111-5. PMID: 16705247.
  4. Dzhokhadze Ta et al., Functional regulation of genome with peptide bioregulators by hypertrophic cardiomyopathy (by patients and relatives), December 1, 2013.
  5. Lezhava T et al., Activation of pericentromeric and telomeric heterochromatin in cultured lymphocytes from old individuals, 01 Apr 2007.
  6. [Effect of peptide bioregulator and cobalt ions on the activity of NORs and associations of acrocentric chromosomes in lymphocytes of patients with hypertrophic cardiomyopathy and their relatives]. Georgian Med News. 2014 Sep;(234):134-7. Russian.
  7. Kost NV, Sokolov OIu, Gabaeva MV, Zolotarev IuA, Malinin VV, Khavinson VKh. Vliianie novykh peptidnykh bioreguliatorov livagena i épitalona na énkefalindegradiruiushchie fermenty syvorotki krovi cheloveka [Effect of new peptide bioregulators livagen and epitalon on enkephalin-degrading enzymes in human serum]. Izv Akad Nauk Ser Biol. 2003 Jul-Aug;(4):427-9.
  8. Girls K, Rónai AZ. Supraspinal delta- and mu-opioid receptors mediate gastric mucosal protection in the rat. J Pharmacol Exp Ther. 2001 Jun;297(3):1010-5. PMID: 11356923.
  9. Lezhava TA. Funktsional'nye osobennosti khromosom cheloveka i starenie [Human chromosome functional characteristics and aging]. Adv Gerontol. 2001;8:34-43. Russian. PMID: 11582753.

Dr. Marinov

Dr. Marinov (MD, Ph.D.) is a researcher and chief assistant professor in Preventative Medicine & Public Health. Prior to his professorship, Dr. Marinov practiced preventative, evidence-based medicine with an emphasis on Nutrition and Dietetics. He is widely published in international peer-reviewed scientific journals and specializes in peptide therapy research.

    Your Cart
    Your cart is empty